Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06351917




Registration number
NCT06351917
Ethics application status
Date submitted
2/04/2024
Date registered
8/04/2024
Date last updated
5/12/2024

Titles & IDs
Public title
Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain
Scientific title
Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain
Secondary ID [1] 0 0
LEVEXE
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Knee Joint Pain 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PlexoZome® Levagen® topical spray solution
Treatment: Drugs - Placebo topical spray solution

Experimental: PlexoZome® Levagen® - PlexoZome® Levagen® topical spray solution applied as 3 full pumps on the affected knee area providing 5.6mg of active per 3 pumps.

Placebo comparator: Placebo Comparator - Placebo topical spray solution applied as 3 full pumps on the affected knee area providing 0mg of active per 3 pumps.


Treatment: Drugs: PlexoZome® Levagen® topical spray solution
PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump

Treatment: Drugs: Placebo topical spray solution
Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Joint pain
Timepoint [1] 0 0
Up to 5 knee pain treatment events for up to 4 weeks
Secondary outcome [1] 0 0
Time to pain relief
Timepoint [1] 0 0
Up to 5 knee pain treatment events for up to 4 weeks
Secondary outcome [2] 0 0
Number of Adverse Events
Timepoint [2] 0 0
Enrolment period
Secondary outcome [3] 0 0
Severity of Adverse Events
Timepoint [3] 0 0
Enrolment period
Secondary outcome [4] 0 0
Rescue medication use
Timepoint [4] 0 0
Up to 5 knee pain treatment events for up to 4 weeks

Eligibility
Key inclusion criteria
* Adults over 20 years
* Generally healthy
* Able to provide informed consent
* Undertaking regular exercise
* Experiencing post exercise knee pain of at least 3 (on a 0-10 scale) at least 2 times in previous 4 weeks
* Agree not to change current diet and/or exercise frequency or intensity
Minimum age
20 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Serious illness( 1 ) e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions
* Unstable illness( 2 ) e.g., diabetes and thyroid gland dysfunction
* Current malignancy (excluding BCC) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy
* Active smokers, nicotine use, alcohol( 3 ) or drug (prescription or illegal substances) abuse
* Allergic to any of the ingredients in the active or placebo formula
* Pregnant or lactating women
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion

Footnotes

( 1 )A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

( 2 )An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity.

( 3 )Chronic past and/or current alcohol use (>14 alcohol drinks/week)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/04/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/06/2024
Sample size
Target
Accrual to date
Final
80
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
RDC Clinical Pty Ltd - Brisbane
Recruitment postcode(s) [1] 0 0
4006 - Brisbane

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
RDC Clinical Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Amanda Rao, PhD
Address 0 0
RDC Clinical Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Amanda Rao, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 414 488 559
Fax 0 0
Email 0 0
amanda@rdcglobal.com.au
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06351917